The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
Open accessAbstract
Purpose: To measure residual disease after neoadjuvant chemotherapy in order to improve the prognostic information that can be obtained from evaluating pathologic response. Patients and Methods: Pathologic slides and reports were reviewed from 382 patients in two different treatment cohorts: sequential paclitaxel (T) then fluorouracil, doxorubicin, and cyclophosphamide (FAC) in 241 patients; and a single regimen of FAC in 141 patients. Residual cancer burden (RCB) was calculated as a continuous index combining pathologic measurements of primary tumor (size and cellularity) and nodal metastases (number and size) for prediction of distant relapse-free survival (DRFS) in multivariate Cox regression analyses. Results: RCB was independently prognostic in a multivariate model that included age, pretreatment clinical stage, hormone receptor status, hormone therapy, and pathologic response (pathologic complete response [pCR] v residual disease [RD]; hazard ratio = 2.50; 95% CI 1.70 to 3.69; P < .001). Minimal RD (RCB-I) in 17% of patients carried the same prognosis as pCR (RCB-0). Extensive RD (RCB-III) in 13% of patients was associated with poor prognosis, regardless of hormone receptor status, adjuvant hormone therapy, or pathologic American Joint Committee on Cancer stage of residual disease. The generalizability of RCB for prognosis of distant relapse was confirmed in the FAC-treated validation cohort. Conclusion: RCB determined from routine pathologic materials represented the distribution of RD, was a significant predictor of DRFS, and can be used to define categories of near-complete response and chemotherapy resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harrell, F. E. (2001) · Springer Series in Statistics · doi:10.1007/978-1-4757-3462-1 · Cited by 9,195
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2672 · Cited by 2,165
Kuerer, H. M., Newman, L. A., Smith, T. L., Ames, F. C., Hunt, K. K., Dhingra, K., Theriault, R. L., Singh, G., Binkley, S. M., Sneige, N., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.460 · Cited by 1,330
Self-citationRevision of the American Joint Committee on Cancer Staging System for Breast Cancer
Singletary, S. E., Allred, C., Ashley, P., Bassett, L. W., Berry, D., Bland, K. I., Borgen, P. I., Clark, G., Edge, S. B., Hayes, D. F., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.026 · Cited by 1,173
Self-citationAssessing the Generalizability of Prognostic Information
Justice, A. C., Covinsky, K. E., & Berlin, J. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00016 · Cited by 1,160
Ogston, K. N., Miller, I. D., Payne, S., Hutcheon, A. W., Sarkar, T. K., Smith, I., Schofield, A., & Heys, S. D. (2003) · The Breast · doi:10.1016/s0960-9776(03)00106-1 · Cited by 982
Bear, H. D., Anderson, S., Smith, R. E., Geyer, C. E., Mamounas, E. P., Fisher, B., Brown, A. M., Robidoux, A., Margolese, R., Kahlenberg, M. S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.1665 · Cited by 943
Berry, D. A., Cirrincione, C., Henderson, I. C., Citron, M. L., Budman, D. R., Goldstein, L. J., Martino, S., Perez, E. A., Muss, H. B., Norton, L., et al. (2006) · JAMA · doi:10.1001/jama.295.14.1658 · Cited by 731
Kaufmann, M., Hortobagyi, G. N., Goldhirsch, A., Scholl, S., Makris, A., Valagussa, P., Blohmer, J.-U., Eiermann, W., Jackesz, R., Jonat, W., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.6187 · Cited by 725
Self-citationPrimary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.
Bonadonna, G., Valagussa, P., Brambilla, C., Ferrari, L., Moliterni, A., Terenziani, M., & Zambetti, M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.93 · Cited by 566
Hortobagyi, G. N., Ames, F. C., Buzdar, A. U., Kau, S. W., McNeese, M. D., Paulus, D., Hug, V., Holmes, F. A., Romsdahl, M. M., Fraschini, G., et al. (1988) · Cancer · doi:10.1002/1097-0142(19881215)62:12<2507::aid-cncr2820621210>3.0.co;2-d · Cited by 504
Self-citationSataloff, D. M., Mason, B. A., Prestipino, A. J., Seinige, U. L., Lieber, C. P., & Baloch, Z. W. (1995) · PubMed · Cited by 429
Hennessy, B. T., Hortobagyi, G. N., Rouzier, R., Kuerer, H., Sneige, N., Buzdar, A. U., Kau, S. W., Fornage, B., Sahin, A., Broglio, K., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5023 · Cited by 420
Self-citationGreen, M. C., Buzdar, A. U., Smith, T., Ibrahim, N. K., Valero, V., Rosales, M. F., Cristofanilli, M., Booser, D. J., Pusztai, L., Rivera, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.232 · Cited by 419
Self-citationvon Minckwitz, G., Raab, G., Caputo, A., Schütte, M., Hilfrich, J., Blohmer, J. U., Gerber, B., Costa, S. D., Merkle, E., Eidtmann, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.078 · Cited by 417
Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers
Simon, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8712 · Cited by 382
Mazouni, C., Peintinger, F., Wan-Kau, S., Andre, F., Gonzalez-Angulo, A. M., Symmans, W. F., Meric-Bernstam, F., Valero, V., Hortobagyi, G. N., & Pusztai, L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2271 · Cited by 299
Self-citationChevallier, B., Roche, H. H., Olivier, J. P., et al. (1993) · PubMed · Cited by 269
Judging New Markers by Their Ability to Improve Predictive Accuracy
Kattan, M. W. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.9.634 · Cited by 265
Chevallier, B., Roche, H., Olivier, J. P., Chollet, P., & Hurteloup, P. (1993) · American Journal of Clinical Oncology · doi:10.1097/00000421-199306000-00006 · Cited by 252
Surrogate Endpoints And FDA’s Accelerated Approval Process
Fleming, T. R. (2005) · Health Affairs · doi:10.1377/hlthaff.24.1.67 · Cited by 249
Buzdar, A. U., Singletary, S. E., Theriault, R. L., Booser, D. J., Valero, V., Ibrahim, N., Smith, T. L., Asmar, L., Frye, D., Manuel, N., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3412 · Cited by 242
Self-citationCarey, L. A., Metzger, R., Dees, E. C., Collichio, F., Sartor, C. I., Ollila, D. W., Klauber-DeMore, N., Halle, J., Sawyer, L., Moore, D. T., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji206 · Cited by 202
On Distributions and Their Transformation to Normality
Draper, N. R., & Cox, D. R. (1969) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1969.tb00806.x · Cited by 199
Rajan, R., Poniecka, A., Smith, T. L., Yang, Y., Frye, D., Pusztai, L., Fiterman, D. J., Gal‐Gombos, E., Whitman, G., Rouzier, R., et al. (2004) · Cancer · doi:10.1002/cncr.20134 · Cited by 162
Self-citationThomas, E. S., Holmes, F. A., Smith, T. L., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.207 · Cited by 147
Resampling and cross-validation techniques: a tool to reduce bias caused by model building?
Schumacher, M. C., Holländer, N., & Sauerbrei, W. (1997) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19971230)16:24<2813::aid-sim701>3.0.co;2-z · Cited by 143
Jones, R. L., Lakhani, S. R., Ring, A. E., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602950 · Cited by 115
What do we mean by validating a prognostic model?
(2000) · doi:10.1002/(sici)1097-0258(20000229)19:4<453::aid-sim350>3.0.co;2-5
Cited by
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., Szallasi, Z., Barry, W. T., Winer, E. P., Tung, N. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2477 · Cited by 1,136
Self-citation
Metadata
- Authors
- Symmans, W. F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., Assad, L., Poniecka, A., Hennessy, B., Green, M., Buzdar, A. U., Singletary, S. E., Hortobagyi, G. N., & Pusztai, L.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-10-01
- Volume
- 25
- Issue
- 28
- Pages
- 4414-4422
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2096145980
- Cited by
- 1,654
- References
- 29
- FWCI
- 11.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.